Bromelain (pharmacology)

Bromelain in pharmacology describes the use of bromelain (a concentrate of proteolytic enzymes from the pineapple plant) in medicine. Bromelain is approved in Europe for the debridement (removal of eschar, that is dead and damaged tissue) of severe burn wounds under the trade name NexoBrid.[1] In the US, it has completed Phase III clinical trials and has the tentative trade name Debrase. It was developed by MediWound, Germany; and Teva is responsible for development and marketing in the US.[2]

Bromelain (pharmacology)
Clinical data
Trade namesNexoBrid
AHFS/Drugs.comUK Drug Information
Routes of
administration		Locally onto the wound
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityDepends on wound surface and depth
Protein binding~50% (bromelain)
Elimination half-life11.7±3.5 (8.5–19.9) hrs
Identifiers
ChemSpider
  • none
Chemical and physical data
FormulaVaries

The medicine has been granted orphan drug status by the European Medicines Agency (EMA).[3]

In other contexts, bromelain has been researched for possible anti-inflammatory effects in treating a range of conditions or diseases, but results of these studies are mixed and regarded as preliminary.[4]

Medical uses

The medication is approved for burns of degrees IIb, i.e. deep partial skin thickness burns, to III, i.e. full thickness burns, and has been shown to significantly reduce the necessity of surgical debridement (15% versus 63% under standard treatment) and skin transplants (18% versus 34%) in a randomized controlled trial.[3][5]

The concentrate is solved in a sterile gel basis, applied onto the burn wound, covered with a wound dressing, and removed after four hours. The healthy surrounding skin has to be protected with a sterile paraffin ointment. The EMA recommends that the treatment should be used in only hospitals having specialised burns centres.[1]

Contraindications and adverse effects

Predictably, the bromelain gel is contraindicated in persons allergic to pineapple or the enzyme papain.[1]

The most common side-effects are fever (19% of patients in studies) and local pain (3.6%). Wound infections occur no more frequently than under standard treatment.[1]

Interactions

The enzymes in NexoBrid inhibit the liver enzymes CYP2C8 and CYP2C9 when ingested. These are involved in the breaking down of a number of drugs, including amiodarone, chloroquine, ibuprofen, and warfarin. It is not known whether this mechanism has any clinical relevance.[6]

Pharmacokinetics

Depending on the surface area and depth of the wound, bromelain blood serum concentrations of no more than 40 µg/ml are expected, with peak concentrations reached after 2 to 4 hours. The terminal half-life varied between 8.5 and 19.9 hours in studies. These data have been obtained from 15 patients with comparatively shallow wounds.[3][6]

Chemistry

The medication is extracted from the stem of the pineapple plant (Ananas comosus)[6] by a standardised process, and each lot has to be analysed for its chemical composition. It contains a mixture of proteolytic enzymes, the main compound being stem bromelain. Bromelain is thought to be the active ingredient, but this has not been determined in studies.[3]

The gel basis contains water, polyacrylic acid as a gelling agent, and a disodium hydrogen phosphate/sodium hydroxide buffer.[3]

References
  1. "EPAR summary for the public: NexoBrid" (PDF). European Medicines Agency. December 2012.
  2. "New Drugs Online Report for bromelain". Uk Medicines Information. Retrieved 28 March 2015.
  3. A. Klement (2 February 2015). "NexoBrid". Österreichische Apothekerzeitung (in German) (3/2015): 10f.
  4. "Bromelain". National Center for Complementary and Integrative Health, US National Institutes of Health. 24 September 2017. Retrieved 17 December 2018.
  5. Rosenberg, L; Krieger, Y; Bogdanov-Berezovski, A; Silberstein, E; Shoham, Y; Singer, A. J. (2014). "A novel rapid and selective enzymatic debridement agent for burn wound management: A multi-center RCT". Burns. 40 (3): 466–74. doi:10.1016/j.burns.2013.08.013. PMID 24074719.
  6. "Summary of Product Characteristics: NexoBrid" (PDF). European Medicines Agency.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.